Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,156.00
Bid: 11,500.00
Ask: 12,270.00
Change: 0.00 (0.00%)
Spread: 770.00 (6.696%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Stocks lag, dollar advances on COVID-19 concerns

Mon, 25th Jan 2021 20:30

By Matt Scuffham

NEW YORK, Jan 25 (Reuters) - Global stocks lagged and the
dollar advanced in volatile markets on Monday, with sentiment
hit by increasing COVID-19 cases, delays in vaccine supplies and
uncertainty over a $1.9 trillion U.S. stimulus plan.

Equity markets have scaled record highs in recent days on
bets vaccines will start to reduce infection rates worldwide and
on a stronger U.S. economic recovery under President Joe Biden.

However, investors are wary about towering valuations amid
questions over the efficacy of the vaccines in curbing the
pandemic and as U.S. lawmakers continue to debate a coronavirus
aid package.

"The risk for these markets is that, after a bumper couple
of months, investors may start to wonder whether they're looking
a little frothy," said Craig Erlam, senior market analyst at
OANDA Europe.

U.S. stocks were mixed. The Nasdaq index hit a record high
on hopes of bumper earnings later this week from mega-cap
technology companies but the Dow Jones Industrial Average index
struggled to keep pace.

By 2:51 PM ET, the Dow Jones Industrial Average fell
107.51 points, or 0.35%, to 30,889.47, the S&P 500 gained
6.8 points, or 0.18%, to 3,848.27 and the Nasdaq Composite
added 67.86 points, or 0.5%, to 13,610.92.

European shares closed at two-week lows as a slump in German
business morale underscored the damage from tighter COVID-19
restrictions.

The pan-European STOXX 600 index reversed early
gains and finished 0.8% lower. The German DAX fell
1.7%, France CAC 40 was down 1.6% and the UK's FTSE 100
declined 0.8%.

The MSCI world equity index, which tracks
shares in 49 nations, rose 0.48 points or 0.07%, to 667.17.

All eyes were on Washington, D.C., as U.S. lawmakers agreed
that getting COVID-19 vaccines to Americans should be a priority
even as they locked horns over the size of the pandemic relief
package.

Financial markets have been eyeing a massive package, though
disagreements have meant months of indecision in a country
suffering more than 175,000 COVID-19 cases a day with millions
out of work.

"The immediate question now is when stimulus aid will be
approved and how much?," asked Christopher Grisanti, chief
equity strategist at MAI Capital Management.

The dollar advanced to a near one-week high against a basket
of currencies, as volatility in stock markets around the globe
sapped investors' appetite for riskier currencies.

The dollar index, which tracks the greenback versus a
basket of six currencies, rose 0.129 points or 0.14 percent, to
90.367. The euro was down 0.28 percent, at $1.2136.

Gold prices pared gains on Monday as the dollar edged
higher. Spot gold prices rose $3.06 or 0.17 percent, to
$1,855.61 an ounce. U.S. gold futures settled 0.1% lower
to $1,855.20 per ounce.

As global COVID-19 cases inched toward 100 million, with
more than 2 million dead, investors digested mixed news on the
progress of vaccine roll-outs.

Moderna Inc said it believes its COVID-19 vaccine
protects against new variants found in Britain and South Africa.
Moderna shares rose 10.3%.

AstraZeneca is not doing enough to try to resolve a
dispute over delayed COVID-19 vaccine deliveries to the European
Union, the bloc's top health official said, as news emerged the
drugmaker is also facing supply problems elsewhere.
U.S. investors were also awaiting a busy earnings week, with
tech giants Apple Inc, Facebook Inc, Tesla Inc
and Microsoft Corp all due to report results.
Sentiment in Asia was boosted by a report that China had
surpassed the United States as the largest recipient of foreign
direct investment in 2020, with $163 billion in inflows.

MSCI's broadest index of Asia-Pacific shares outside Japan
rose 9.21 points or 1.28%.

In commodity markets, Brent crude settled at $55.88
a barrel, up 47 cents or 0.85%. U.S. crude settled at
$52.77 a barrel, up 50 cents or 0.96%.

(Reporting by Matt Scuffham; Additional reporting by Devik Jain
and Shreyashi Sanyal in Bengaluru; Editing by Andrea Ricci)

More News
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more
3 Jan 2024 07:54

LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data

(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.

Read more
2 Jan 2024 17:05

British equities slip on higher yields, financials drag

FTSE 100 down 0.2%, FTSE 250 off 0.9%

*

Read more
2 Jan 2024 12:01

LONDON MARKET MIDDAY: London stocks make largely soft start to 2024

(Alliance News) - Stock prices in London were mostly lower at midday on Tuesday in a slow start to the new year, reacting to the UK manufacturing sector finishing a tricky 2023 with a further contraction in December.

Read more
2 Jan 2024 11:00

Weight-loss drugs: Who, and what, are they good for?

Jan 2 (Reuters) - Powerful weight-loss medicines like Novo Nordisk's Wegovy leapt into public view in 2023, from social media to doctors' offices and cocktail parties, offering a new way to address record obesity rates.

Read more
2 Jan 2024 11:00

What other health conditions might weight-loss drugs treat?

Jan 2 (Reuters) - Novo Nordisk's blockbuster diabetes drug Ozempic and weight-loss therapy Wegovy are being studied to see whether they can improve health in other ways.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.